X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The License Agreement grants Sunshine Biopharma exclusive worldwide rights for all of the University of Arizona and University of Illinois Chicago technology pertaining to PLpro protease inhibitors of SARS-CoV-2, the coronavirus that causes COVID-19.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: University of Arizona
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 28, 2023
Details:
The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through IND-enabling studies. At any time the research results become conclusive, company will proceed to conducting a Phase I clinical trial.
Lead Product(s): Adva-27a
Therapeutic Area: Oncology Product Name: Adva-27a
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jewish General Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2023
Details:
The Company’s collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1.
Lead Product(s): K1.1
Therapeutic Area: Oncology Product Name: K1.1
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2022
Details:
Recently communicated mRNA molecules GEM-difluorinated C-glycoside Derivative of Podophyllotoxin found in pre-clinical trials is effective at destroying cancer cells grown in culture.
Lead Product(s): mRNA Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer, is able to destroy cancer cells through the inhibition of a key cell-cycle enzyme called Topoisomerase II.
Lead Product(s): GEM-difluorinated C-glycoside Derivative of Podophyllotoxin
Therapeutic Area: Oncology Product Name: Adva-27a
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
The development of the PLpro inhibitor, SBFMPL4, is currently continuing at the University of Georgia. At the University of Arizona, the research effort will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties.
Lead Product(s): SBFM-PL4
Therapeutic Area: Infections and Infectious Diseases Product Name: SBFM-PL4
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Arizona
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 25, 2022
Details:
Certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration for treatment of neurodegenerative disorders.
Lead Product(s): mRNA Antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
. By escaping the efflux pump of P-glycoprotein, Adva-27a is able to accumulate inside cancer cells and destroy them by inhibiting Topoisomerase II, a DNA unwinding enzyme preferentially used by cancer cells to multiply.
Lead Product(s): GEM-difluorinated C-glycoside derivative of Podophyllotoxin
Therapeutic Area: Oncology Product Name: Adva-27a
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Details:
Adva-27a is a unique anticancer compound targeted for multidrug resistant cancer. This newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033.
Lead Product(s): GEM-difluorinated C-glycoside derivative of Podophyllotoxin
Therapeutic Area: Oncology Product Name: Adva-27a
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
Sunshine Biopharma has signed a license agreement with the University of Georgia for two Anti-Covid compounds which UGA had previously developed and patented. Sunshine Biopharma and UGA will advance the development of these two compounds in parallel with SBFM-PL4.
Lead Product(s): SBFM-PL4
Therapeutic Area: Infections and Infectious Diseases Product Name: SBFM-PL4
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: University of Georgia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
